January 13, 2025 - 02:56

ALAMEDA, Calif., January 12, 2025—Exelixis, Inc. has announced its preliminary unaudited financial results for the fiscal year 2024, alongside financial guidance for the upcoming fiscal year 2025. The company is optimistic about the potential for significant advancements in clinical and regulatory efforts, particularly concerning its cabozantinib franchise.
In 2025, Exelixis plans to focus on executing its clinical programs and anticipates multiple data readouts for zanzalintinib, as well as developments across its diverse pipeline of small molecules and biotherapeutics. The company aims to leverage its existing assets while exploring new opportunities to enhance its market position.
With a clear strategy in place, Exelixis is poised for a year of growth, innovation, and impactful milestones that could shape the future of its therapeutic offerings. The commitment to advancing patient care remains at the forefront of Exelixis's mission as it navigates the challenges and opportunities ahead.
November 7, 2025 - 11:22
Hidden Treasures in Asia: Three Small-Cap Stocks with High Growth PotentialAs global markets navigate a landscape of mixed performances, large-cap tech stocks are leading the charge in gains, while smaller-cap indexes such as the S&P MidCap 400 and Russell 2000 are...
November 6, 2025 - 19:11
OneStream Reports Strong Financial Performance for Q3 2025OneStream, a prominent player in the enterprise finance management sector, has released its financial results for the third quarter of 2025, showcasing robust growth and resilience in a competitive...
November 6, 2025 - 12:44
The Impact of SNAP Benefits on Walmart's BusinessWalmart, one of the largest retail chains in the United States, heavily relies on Supplemental Nutrition Assistance Program (SNAP) benefits to drive sales. According to Professor Tomas Jandik from...
November 5, 2025 - 21:09
ADP Private Payrolls Highlight Economic Landscape Amid Prolonged US ShutdownIn a significant development, ADP private payrolls have taken the spotlight as the United States experiences its longest government shutdown in history. The ongoing impasse has severely restricted...